i'm now handing over to emer cooke-— to emer cooke. thank you. good afternoon. _ to emer cooke.to a conclusion on the review of cases of blood clots in people vaccinated with astrazeneca's covid-19 _ vaccinated with astrazeneca's covid—19 vaccine. the committee has come _ covid—19 vaccine. the committee has come to— covid—19 vaccine. the committee has come to a _ covid—19 vaccine. the committee has come to a clear scientific conclusion, this is a safe and effective _ conclusion, this is a safe and effective vaccine, its benefits in protecting people from covid—19 with the associated risks of death and hospitalisation outweigh the possible risks. the committee also concluded — possible risks. the committee also concluded that the vaccine is not associated with an increase in the overall— associated with an increase in the overall risk— associated with an increase in the overall risk of thrombotic events or blood _ overall risk of thrombotic events or blood clots — overall risk of thrombotic events or blood clots. during the investigation and review we began to see a _ investigati

referring to occurance of blood clots in recipients of the vaccine, the ema's executive director, emer cookee is no indication that vaccination has caused these conditions. they have not come up in clinical trials and they are not listed as known or expected side effects with this vaccine. in clinical trials, effects with this vaccine. in clinicaltrials, both effects with this vaccine. in clinical trials, both the vaccinated people and the people who received the placebo have shown small, some very small numbers of blood clots developments. we, the number of thromboembolic events seems not to have be higher than that seen in the general population. i don't need to remind you all today that the covid—19 pandemic is a global crisis. it continues to be a major burden on eu health systems. vaccines for covid—19 help to protect individuals from becoming ill, especially health care professionals and vulnerable populations such as older people and those with chronic diseases. this is a very important consideration in our assessment of the benefit risk. while the investigation is ongoing, we are cur

earlier, emer cooke from the european medicines agency said the committee would continue to study possibleof cases of blood clots and people back with astrazeneca covid—19 vaccine. the committee has come to a clear scientific conclusion. this is a safe and effective vaccine. its benefits in protecting people from covid—19 with the associated risks of death and hospitalisation outweigh the possible risks. the committee also concluded that there vaccine is not associated with an increase in the overall risk of thromboembolic events for blood clots. now, during the investigation and review we began to see a small number of cases of rare and unusual but very serious clotting disorders and this triggered a more focused review. based on the evidence available and after days of in—depth analysis of lab results, clinical reports, autopsy reports and further information for the clinical trials we still cannot rule out definitively a link between these cases and there vaccine. professor adam finn is from the university of bristol and sits on the government'sjoint committee on vaccination and immunis

speaking at a news conference in the past hour, the regulator's executive director, emer cooke, saidible links between rare blood clots and the vaccine. our expert committee on the safety of medicines, the pharmaceutical vigilance risk committee, has now come to a conclusion on the review of cases of blood clots in people vaccinated with astrazeneca's covid—19 vaccine. the committee has come to a clear scientific conclusion. this is a safe and effective vaccine. its benefits in protecting people from covid—19 with the associated risks of death and hospitalisation outweigh the possible risks. the committee also concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots. now, during the investigation and review we began to see a small number of cases of rare and unusual but very serious clotting disorders and this then triggered a more focused review. based on the evidence available and after days of in—depth analysis of lab results, clinical reports, autopsy reports and further information from the clinical trials, we stil